Table 2. Clinico-pathological data of ovarian cancer cohort sorted by blood group.
| ABO blood group | |||||||
|---|---|---|---|---|---|---|---|
| ALL | O | A | AB | B | p | n | |
| Characteristic | |||||||
| Number of women | 282 | 100 | 138 | 10 | 34 | 282 | |
| Percentage of total (%) | 100 | 35.46 | 48.94 | 3.55 | 12.06 | ||
| Cancer Center | 0.16 | 282 | |||||
| Basel | 160 (56.7%) | 55 (55.0%) | 85 (61.6%) | 6 (60.0%) | 14 (41.2%) | ||
| Sydney | 87 (30.9%) | 36 (36.0%) | 33 (23.9%) | 3 (30.0%) | 15 (44.1%) | ||
| Zürich | 35 (12.4%) | 9 (9.00%) | 20 (14.5%) | 1 (10.0%) | 5 (14.7%) | ||
| Mean age (years) (±SD) | 60.7 (13.7) | 61.1(13.9) | 60.2 (13.3) | 57.4 (12.3) | 63.1 (15.1) | 0.599 | 276 |
| Tumour type | 0.397 | 282 | |||||
| Adenocarcinoma | 257 (91.1%) | 93 (93.0%) | 123 (89.1%) | 10 (100%) | 31 (91.2%) | ||
| Carcinosarcoma (MMMT) | 13 (4.61%) | 6 (6.00%) | 5 (3.62%) | 0 (0.00%) | 2 (5.88%) | ||
| Carcinoid | 1 (0.35%) | 1 (1.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
| Brenner tumor | 3 (1.06%) | 0 (0.00%) | 2 (1.45%) | 0 (0.00%) | 1 (2.94%) | ||
| Sertoli-Leydig tumor | 2 (0.71%) | 0 (0.00%) | 2 (1.45%) | 0 (0.00%) | 0 (0.00%) | ||
| Granulosacell tumor | 6 (2.13%) | 0 (0.00%) | 6 (4.35%) | 0 (0.00%) | 0 (0.00%) | ||
| Histology | 0.645 | 261 | |||||
| Serous | 160 (61.3%) | 53 (56.4%) | 83 (65.9%) | 4 (40.0%) | 20 (64.5%) | ||
| Endometrioid | 42 (16.1%) | 16 (17.0%) | 18 (14.3%) | 2 (20.0%) | 6 (19.4%) | ||
| Mucinous | 21 (8.05%) | 8 (8.51%) | 8 (6.35%) | 1 (10.0%) | 4 (12.9%) | ||
| Clear cell | 11 (4.21%) | 5 (5.32%) | 4 (3.17%) | 2 (20.0%) | 0 (0.00%) | ||
| Neuroendocrine | 1 (0.38%) | 1 (1.06%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||
| Mixed/unknown/other | 26 (9.96%) | 11 (11.70%) | 13 (10.32%) | 1 (10.0%) | 1 (3.23%) | ||
| FIGO Stage | 0.59 | 247 | |||||
| I | 64 (25.9%) | 22 (23.9%) | 27 (23.7%) | 4 (40.0%) | 11 (35.5%) | ||
| II | 21 (8.50%) | 10 (10.9%) | 8 (7.02%) | 1 (10.0%) | 2 (6.45%) | ||
| III | 126 (51.0%) | 44 (47.8%) | 61 (53.5%) | 4 (40.0%) | 17 (54.8%) | ||
| IV | 36 (14.6%) | 16 (17.4%) | 18 (15.8%) | 1 (10.0%) | 1 (3.23%) | ||
| Tumour grade | 0.519 | 216 | |||||
| G1 | 34 (15.7%) | 14 (17.5%) | 14 (13.7%) | 1 (12.5%) | 5 (19.2%) | ||
| G2 | 35 (16.2%) | 17 (21.2%) | 12 (11.8%) | 1 (12.5%) | 5 (19.2%) | ||
| G3 | 147 (68.1%) | 49 (61.3%) | 76 (74.5%) | 6 (75.0%) | 16 (61.5%) | ||
| Residual Disease | 0.783 | 170 | |||||
| optimal debulking | 106 (62.4%) | 41 (61.2%) | 47 (62.7%) | 5 (83.3%) | 13 (59.1%) | ||
| suboptimal debulking | 64 (37.6%) | 26 (38.8%) | 28 (37.3%) | 1 (16.7%) | 9 (40.9%) | ||
| Survival status | 0.781 | 274 | |||||
| alive | 226 (82.5%) | 81 (82.7%) | 107 (80.5%) | 9 (90.0%) | 29 (87.9%) | ||
| dead of disease | 48 (17.5%) | 17 (17.3%) | 26 (19.5%) | 1 (10.0%) | 4 (12.1%) | ||
| Recurrence | 0.128 | 282 | |||||
| no | 174 (61.7%) | 67 (67.0%) | 86 (62.3%) | 6 (60.0%) | 15 (44.1%) | ||
| yes | 108 (38.3%) | 33 (33.0%) | 52 (37.7%) | 4 (40.0%) | 19 (55.9%) | ||
Data from gynecological cancer centers (Basel and Zürich, Switzerland) and Sydney (Australia) collected between 1974 and 2014. P-values calculated by T-Tests or Fisher’s exact Tests.